Born: 1949
Education: BSc Uppsala University, Medical degree Linköping University.
Experience: Göran Ando has over 30 years’ experience in the pharmaceutical industry. He began his career in 1978 as Medical Director of Pfizer AB and continued as head of clinical research with Pfizer International in the USA. Dr. Ando then became VP, Medical and Scientific Affairs at Bristol-Myers and also returned to Sweden as President of the Astra Research Center. Between 1989 and 1995, he held a number of senior positions at Glaxo, including head of research and development for Glaxo Group Research. Dr. Ando joined Pharmacia AB in 1995 as Executive Vice President and Deputy CEO and moved to the United States in 1997 to lead research and development with additional responsibilities for manufacturing, information technology, business development and mergers and acquisitions. During his eight-year tenure as head of research and development at Pharmacia / Pharmacia & Upjohn, 17 new drugs were approved by the FDA, prior to Pfizer’s acquisition of Pharmacia.
Dr. Ando was then named CEO of Celltech Group PLC in the UK, one of the most successful European biotechnology companies, until it was acquired by UCB Pharma in 2005.
Göran Ando was elected in 2005 as a board member of Novo Nordisk A / S, where he became Vice Chairman in 2006 and Chairman between 2013 and 2018.
Other positions: Göran Ando serves as Chairman of the Board of Eyepoint Pharmaceuticals (USA) and also serves as Chairman of Nouscom AG (Switzerland).
Holdings in Nanexa: 1 040 000 shares.
Göran Ando is independent in relation to the company, the company management and the company’s major shareholders
Born: 1964
Education: BSc in Business Administration and Executive MBA from the School of Business, Economics and Law at the University of Gothenburg
Experience: Eva Nilsagård has over 30 years’ experience in senior positions, primarily in the automotive and medtech/biotech industries, such as CFO for Vitrolife, Plastal Industri and OptiGroup, Senior VP Strategy & Business development at Volvo Group Sales & Marketing EMEA, and senior positions in AstraZeneca and AB Volvo. She is Founder and CEO of Nilsagård Consulting AB, where in recent years she has held several interim positions as CEO and CFO. Professional Board career with involvement in listed, private and state-owned companies where she, among other things, contributed expertise in audit committee work and corporate governance and was involved in several IPOs. For the past ten years, Eva has acted as a mentor to several young female leaders.
Other positions: Board member of Addlife AB, Bufab AB (publ), Hansa Biopharma AB, Nimbus Group AB, Xbrane Biopharma AB and AB Svensk Exportkredit, Chairman of the Board of Spermosens AB and President and Board member of Nilsagård Consulting AB.
Holdings in Nanexa: 180 000 shares, via companies
Born: 1950
Education: BSc in Medicine and Doctor of Medicine (MD) at Lund University. Associate professor at Karolinska Institutet.
Experience: Magnus Westgren has previously been Head of Obstetrics at Karolinska University Hospital and has been a professor at Karolinska Institutet since 2006. Postdoctoral work 1984–1985 at the Department of Obstetrics and Gynecology at Women’s Hospital University of Southern California. Magnus has also been a scientific consultant and advisor to the National Board of Health and Welfare, supervisor for 30 doctoral students and has published more than 300 scientific papers. He is a Fellow of the Royal College of Obstetricians and Gynecologists.
Other positions: Chairman of the Board of MedSciNet AB, Board member of BoostPharma ApS and Westknow AB and Senior Professor at Karolinska Institutet.
Holdings in Nanexa: 253 464 shares. Related party holdings: 700 shares.
Magnus Westgren is independent in relation to the company, the company management and the company’s major shareholders, respectively.
Born: 1948
Education: BSc in Pharmacy, MSc of Pharmacy (MPharm), Uppsala University
Experience: Birgit Stattin Norinder has extensive experience from pharma and biotech companies in Sweden, the USA and the United Kingdom. She has led several Research and Development departments and has been behind a number of new and approved drugs. Birgit has been CEO and Chairman of Prolifix Ltd, Senior Vice President Worldwide Development at Pharmacia & Upjohn and Director International Regulatory Affairs at Glaxo Group Research Ltd. Birgit has also held a number of positions as a Board member and Chairman of European biotechnology companies.
Other positions: Board member of AddLife AB.
Holdings in Nanexa: 60 000 shares
Birgit Stattin Norinder is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Born: 1973
Education: Doctor of Philosophy (PhD) in Pharmacology and Bachelor of Science in Biochemical Pharmacology from University of Leicester, UK
Experience: Richard has many years of experience as an investor and executive in pharmaceutical development companies. Richard previous experience i.a. from positions as Global Oncology Venture and Transaction Lead at Johnson and Johnson, CEO of European clinical stage biotechnology company Trino Therapeutics, and Investment Manager and responsible for direct healthcare investments and venture capital funds at Wellcome Trust. Richard has been on the board of a number of biotech companies and worked closely with management teams on strategy, financing and exits via licensing, M&A and public listings.
Other positions: Chief Business and Operating Officer at Nouscom AG (Switzerland).
Holdings in Nanexa: 0
Richard Davis is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Born: 1955
Education: MSc in Economics from University of Copenhagen and an MBA from INSEAD
Experience: Jakob Dynnes Hansen has 30 years of combined experience from biotech and financing. Jakob’s previous experience includes CFO for more than 9 years at Evolva, a Swiss public biotech company, with a key role in the company’s listing and several subsequent financings, and CFO at Danish biotech companies Nuevolution and Zealand Pharma. Before moving into biotech, Jakob was a senior member of the Corporate Finance Team at Unibank (now Nordea) and he has been Head of Market Research at Novo Nordisk.
Other positions: CFO at Zerion Pharma A/S (Denmark) and CFO at Asarina Pharma AB.
Holdings in Nanexa: 250 000 shares
Jakob Dynnes Hansen is independent in relation to the company, the company management and the company’s major shareholders, respectively.
